Trial record 1 of 1 for:    NCT01120691.
Previous Study | Return to List | Next Study

Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations (SPARK)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01120691
First received: May 5, 2010
Last updated: October 29, 2013
Last verified: October 2013
  Purpose

This study is designed to assess the effect of once-daily QVA149 on COPD exacerbations in patients with severe to very severe COPD.


Condition Intervention Phase
Chronic Obstructive Pulmonary Disease
Drug: QVA149
Drug: NVA237
Drug: tiotropium
Drug: Salbutamol/albuterol
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 64-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and Open-label Tiotropium (18 μg o.d.) on COPD Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Rate of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in QVA149 and NVA237 Treatment Arms During the Treatment Period. [ Time Frame: 64 weeks ] [ Designated as safety issue: No ]

    A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as a worsening of two or more of the following major symptoms for at least 2 consecutive days: dyspnea, sputum volume or sputum purulence OR a worsening of any 1 major symptom together with an increase in any 1 of the following minor symptoms for at least 2 consecutive days: sore throat, colds (nasal discharge and/or nasal congestion), fever without other cause, cough or wheezing. A COPD exacerbation was considered of moderate severity if treatment with systemic glucocorticosteroids or antibiotics or both was required and severe if hospitalization was required. An emergency room (ER) visit of longer than 24 hours was considered a hospitalization.

    Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years



Secondary Outcome Measures:
  • Rate of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in QVA149 and Open-label Tiotropium Treatment Arms During the Treatment Period. [ Time Frame: 76 weeks ] [ Designated as safety issue: No ]

    A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as a worsening of two or more of the following major symptoms for at least 2 consecutive days: dyspnea, sputum volume or sputum purulence OR a worsening of any 1 major symptom together with an increase in any 1 of the following minor symptoms for at least 2 consecutive days: sore throat, colds (nasal discharge and/or nasal congestion), fever without other cause, cough or wheezing. A COPD exacerbation was considered of moderate severity if treatment with systemic glucocorticosteroids or antibiotics or both was required and severe if hospitalization was required. An emergency room (ER) visit of longer than 24 hours was considered a hospitalization.

    Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years


  • Time to First Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbation Between QVA149, NVA237 and Open Label Tiotropium During the Treatment Period [ Time Frame: 64 weeks ] [ Designated as safety issue: No ]

    A Chronic Obstructive Pulmonary Disease (COPD) exacerbation was defined as a worsening of two or more of the following major symptoms for at least 2 consecutive days: dyspnea, sputum volume or sputum purulence OR a worsening of any 1 major symptom together with an increase in any 1 of the following minor symptoms for at least 2 consecutive days: sore throat, colds (nasal discharge and/or nasal congestion), fever without other cause, cough or wheezing. A COPD exacerbation was considered of moderate severity if treatment with systemic glucocorticosteroids or antibiotics or both was required and severe if hospitalization was required. An emergency room (ER) visit of longer than 24 hours was considered a hospitalization.

    Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years


  • Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Requiring the Use of Both Systemic Glucocorticosteroids and Antibiotics [ Time Frame: 64 weeks ] [ Designated as safety issue: No ]
    Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years

  • Number of Days With Moderate or Severe Exacerbation That Required Treatment With Systemic Corticosteroids and Antibiotics [ Time Frame: 64 weeks ] [ Designated as safety issue: No ]
    The number of exacerbation days is defined as the sum of the duration of days recorded as an exacerbation for all exacerbations recorded per patient.

  • Time to Study Withdrawal or Premature Discontinuation for Any Reason Between QVA149 (110/50 µg q.d.), NVA237 (50 µg q.d.) and Open Label Tiotropium (18 µg q.d.) During the Treatment Period. [ Time Frame: 64 weeks ] [ Designated as safety issue: No ]
    Time to Study Withdrawal or Premature Discontinuation for Any Reason was analyzed for each treatment group using a Kaplan-Meier estimation for the modified safety set. Patients who did not discontinue early were censored at the final visit of the treatment phase.

  • Percentage of Patients With Study Withdrawal or Premature Discontinuation for Any Reason Between QVA149 (110/50 µg q.d.), NVA237 (50 µg q.d.) and Open Label Tiotropium (18 µg q.d.)During the Treatment Period [ Time Frame: 64 weeks ] [ Designated as safety issue: No ]
    Percentage of Patients With Study Withdrawal or Premature Discontinuation for Any Reason was analyzed for each treatment group using a Kaplan-Meier estimation for the modified safety set. Patients who did not discontinue early were censored at the final visit of the treatment phase.

  • Cumulative Rates of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations for Multiple COPD Exacerbation at Different Time Points [ Time Frame: 26, 52, 64, 76 weeks ] [ Designated as safety issue: No ]
    Cumulative rates were estimated using Anderson and Gill method. Chronic Obstructive Pulmonary Disease (COPD) exacerbations are considered to be moderate if treatment with systemic corticosteroids and/or antibiotics was required. COPD exacerbations are considered to be severe if treatment for moderate severity and hospitalization were required. Rate of moderate or severe exacerbations per year = total number of moderate or severe exacerbations / total number of treatment years

  • Pre-dose Forced Expiratory Volume in 1 Second (FEV-1) After 4, 12, 26, 38, 52 and 64 Weeks of Treatment Between QVA149, NVA237 and Open Label Tiotropium [ Time Frame: 4, 12, 26, 38, 52 and 64 weeks ] [ Designated as safety issue: No ]

    Pulmonary function assessments were performed using centralized spirometry. The spirometer was customized and programmed according to the requirements of the study protocol in accordance with American Thoracic Society (ATS) standards.

    Spirometry measurements taken were FEV1 at -45 minutes and -15 minutes pre-dose. Three acceptable maneuvers had to be performed for each time point. The FEV1 values recorded had to be the highest values measured irrespective of whether or not they occurred on the same curve.

    The mixed model for analysis contained treatment as a fixed effect with average of the 45 minutes and 15 minutes pre dose FEV1 measurements at day 1 as the baseline measurement, FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at -14 Day) as covariates.


  • Pre-dose Forced Vital Capacity (FVC)After 4, 12, 26, 38, 52 and 64 Weeks of Treatment Between QVA149, NVA237 and Open Label Tiotropium [ Time Frame: 4, 12, 26, 38, 52 and 64 weeks ] [ Designated as safety issue: No ]

    Pulmonary function assessments were performed using centralized spirometry. The spirometer was customized and programmed according to the requirements of the study protocol in accordance with American Thoracic Society (ATS) standards.

    Pre-dose Forced Vital Capacity (FVC) is defined as the average of the -15 minutes and the -45 minutes FVC values. Baseline is defined as the average of the -45 minutes and -15 minutes FVC values taken on day 1 prior to first dose. FVC data taken within 6h of rescue medication or within 7 days of systemic corticosteroid is excluded from this analysis


  • Change in Mean Daily Use (Number of Puffs) of Rescue Therapy Between QVA149, NVA237 and Open Label Tiotropium From Baseling Over the 64 Week Treatment Period [ Time Frame: Baseline (14 day run-in), 64 weeks ] [ Designated as safety issue: No ]
    The severe or less FEV1 % predicted (post bronchodilator)>=30%; very severe=> FEV1 % predicted(the post bronchodilator)<30%.Number of puffs of rescue medication taken in the previous 12 hours was recorded in patient diary in the morning and in the evening for 26 weeks.The total number of puffs per day was calculated and divided by the number of days with data to determine the mean daily number of puffs of rescue medication for each patient.Rescue medication data recorded during the 14 day run-in was used to calculate the baseline.A negative change from baseline indicates improvement. A mixed model was used with treatment as a fixed effect with baseline number of puffs and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates.

  • Change From Baseline of Percentage of Days Without Rescue Therapy Use Between QVA149,NVA237 and Open Label Tiotropium Over the 64 Week Treatment Period [ Time Frame: Baseline (14 day run-in), 64 weeks ] [ Designated as safety issue: No ]
    A day with no rescue medication use is defined from the diary data as any day where the patient recorded no rescue medicine use during the previous 12 hours. The percentage of days is calculated by the number of days with no rescue medicine use/total number of days with evaluable data X 100. A mixed model was used with treatment as a fixed effect with baseline number of puffs and FEV1 prior to inhalation and FEV1 60 minutes post inhalation of two short acting bronchodilators (components of reversibility at Day -14) as covariates. The model also included baseline smoking status (current/ex-smoker), baseline ICS use (Yes/No) and region as fixed effects with center nested within region as a random effect.

  • St. George's Respiratory Questionnaire (SGRQ) Scores Between QVA149, NVA237 and Open Label Tiotropium Over 12, 26, 38, 52 and 64 Weeks of Treatment [ Time Frame: 12, 26, 38, 52 and 64 weeks ] [ Designated as safety issue: No ]
    St. George's Respiratory Questionnaire (SGRQ) is a health related quality of life questionnaire consisting of 51 items in three components: symptoms, activity, and impacts. The lowest possible value is zero and the highest 100. Higher values correspond to greater impairment in quality of life. Mixed model used baseline SGRQ, baseline inhaled corticosteroid (ICS) use, Forced Expiratory Volume in 1 Second (FEV1) prior to inhalation of short acting beta-agonist (SABA), and FEV1 45 minutes post-inhalation of SABA as covariates. SGRQ total score is the sum of the scores from the three components; symptoms, activity and impacts.


Enrollment: 2224
Study Start Date: April 2010
Study Completion Date: July 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: QVA149
QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.
Drug: QVA149
QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
Drug: Salbutamol/albuterol
As needed throughout the study
Active Comparator: NVA237
NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.
Drug: NVA237
NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
Drug: Salbutamol/albuterol
As needed throughout the study
Active Comparator: open-label tiotropium
Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks). Salbutamol/albuterol was available for rescue medication use throughout the study.
Drug: tiotropium
Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
Drug: Salbutamol/albuterol
As needed throughout the study

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria :

  1. Male or female adults aged ≥40 years, who had signed an informed consent form prior to initiation of any study-related procedure.
  2. Patients with severe to very severe Chronic Obstructive Pulmonary Disease COPD (Stage III or IV) according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines 2008.
  3. Current or ex-smokers with a smoking history of at least 10 pack years (Ten pack-years were defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years).
  4. Patients with a post-bronchodilator Forced Expiratory Volume in one second ( FEV1) <50% of the predicted normal value, and post-bronchodilator FEV1/ Forced Vital Capacity (FVC) <0.70 at Visit 2 (day -14). (Post refers to 1 h after sequential inhalation of 84 µg (or equivalent dose) of ipratropium bromide and 400 µg of salbutamol).
  5. A documented history of at least 1 COPD exacerbation in the previous 12 months that required treatment with systemic glucocorticosteroids and/or antibiotics.

Exclusion Criteria:

  1. Pregnant women or nursing mothers (pregnancy confirmed by positive urine pregnancy test).
  2. Women of child-bearing potential
  3. Patients requiring long term oxygen therapy (> 15 h a day) on a daily basis for chronic hypoxemia.
  4. Patients who had a COPD exacerbation that required treatment with antibiotics, systemic steroids (oral or intravenous) or hospitalization in the 6 weeks prior to visit 1 or between visit 1 (Day -21) and Visit 3 (Day 1).
  5. Patients who developed a COPD exacerbation during a period between visit 1 and 3 were ineligible but were permitted to be re-screened after a minimum of 6 weeks after the resolution of the COPD exacerbation.
  6. Patients who had a respiratory tract infection within 4 weeks prior to visit 1 (Day -21)

    • Patients who developed an upper or lower respiratory tract infection during the screening period (up to visit 3 (Day 1) were not eligible, but were permitted to be re-screened 4 weeks after the resolution of the respiratory tract infection

  7. Patients with concomitant pulmonary disease, e.g. pulmonary tuberculosis (unless confirmed by chest x-ray to be no longer active), clinically significant bronchiectasis, sarcoidosis, interstitial lung disorder or pulmonary hypertension.
  8. Patients with lung lobectomy, or lung volume reduction or lung transplantation.
  9. Patients who, in the judgment of the investigator, have a clinically relevant laboratory abnormality or a clinically significant condition such as (but not limited to):

    • Unstable ischemic heart disease, left ventricular failure, history of myocardial infarction, arrhythmia (excluding chronic stable Atrial Fibrillation (AF). Patients with such events not considered clinically significant by the investigator may be considered for inclusion in the study
    • history of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases, with the exception of localized basal cell carcinoma of the skin
    • uncontrolled hypo- or hyperthyroidism, hypokalemia or hyper adrenergic state
    • narrow-angle glaucoma
    • Symptomatic prostatic hyperplasia or bladder-neck obstruction or moderate to severe renal impairment or urinary retention. (Patients with a Transurethral Resection of Prostate (TURP) were excluded from the study. Patients who underwent full re-section of the prostate could be considered for the study, as well as patients who were asymptomatic and stable on pharmacological treatment for the condition).
    • any condition which might have compromised patient safety or compliance, interfered with evaluation, or precluded completion of the study
  10. Patients with any history of asthma indicated by (but not limited to) a blood eosinophil count > 600/mm3 (at visit 2), or onset of symptoms prior to 40 years. Patients without asthma were excluded if their eosinophil count was >600/mm3 at visit 2.
  11. Patients with allergic rhinitis who used H1 antagonists or intranasal corticosteroids intermittently (treatment with a constant dose was permitted).
  12. Patients with eczema (atopic), known high immunoglobulin E (IgE) levels or a known positive skin prick test in the last 5 years.
  13. Patients with known history and diagnosis of alpha-1 antitrypsin deficiency.
  14. Patients who were participating in the active phase of a supervised pulmonary rehabilitation program.
  15. Patients with Type I or uncontrolled Type II diabetes.
  16. Patients contraindicated for treatment with, or having a history of reactions/ hypersensitivity to any of the following inhaled drugs or drugs of a similar class or any component thereof:

    • anticholinergic agents
    • long and short acting beta-2 agonists
    • sympathomimetic amines.
  17. Patients with a history of long QT syndrome or whose corrected QT interval (QTc) measured at visit 2 (Day -14) (Fridericia method) was prolonged (>450 ms for males and females) as confirmed by the central ECG assessor.
  18. Patients with a clinically significant abnormality on the screening or baseline ECG who in the judgment of the investigator would be at potential risk if enrolled into the study. (These patients could not be re-screened).
  19. Patients who needed treatments for COPD and allied conditions after the start of the study (visit 1)
  20. Patients who needed treatments for COPD and allied conditions (e.g. allergic rhinitis) unless they had been stabilized
  21. Patients taking other prohibited medications
  22. Patients unable to use a dry powder inhaler (e.g. single dose dry powder inhaler (SDDPI), HandiHaler® device, or pressurized Metered Dose Inhaler (MDI) (rescue medication).
  23. Patients unable to use an electronic patient diary.
  24. Patients who were, in the opinion of the investigator known to be unreliable or non-compliant.
  25. Patients who used other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of visit 1 (day -21), whichever was longer.
  26. Patients who had live attenuated vaccination within 30 days prior to the screening visit or during the run-in period. Inactivated influenza vaccination, pneumococcal vaccination or any other inactivated vaccine was acceptable provided it was not administered within 48 hours prior to screening and randomization visits.

No additional exclusions were applied by the investigator, in order to ensure that the study population was representative of all eligible patients.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01120691

  Hide Study Locations
Locations
United States, Alabama
Novartis Investigative Site
Birmingham, Alabama, United States, 35233
Novartis Investigative Site
Fairhope, Alabama, United States, 36532
Novartis Investigative Site
Florence, Alabama, United States, 35630
Novartis Investigative Site
Homewood, Alabama, United States, 35209-6870
Novartis Investigative Site
Jasper, Alabama, United States, 35501
United States, Arkansas
Novartis Investigative Site
Pine Bluff, Arkansas, United States, 71603
United States, California
Novartis Investigative Site
Fullerton, California, United States, 92835
Novartis Investigative Site
Palo Alto, California, United States, 94304-1207
Novartis Investigative Site
Riverside, California, United States, 92506
Novartis Investigative Site
San Diego, California, United States, 92120
Novartis Investigative Site
San Diego, California, United States, 92101
Novartis Investigative Site
San Diego, California, United States, 92103-8415
Novartis Investigative Site
Stockton, California, United States, 95207
United States, Florida
Novartis Investigative Site
Gainesville, Florida, United States, 32608
Novartis Investigative Site
Miami, Florida, United States, 33125
Novartis Investigative Site
Pensacola, Florida, United States, 32503
United States, Idaho
Novartis Investigative Site
Couer D'Alene, Idaho, United States, 83814
United States, Illinois
Novartis Investigative Site
Normal, Illinois, United States, 61761
Novartis Investigative Site
River Forest, Illinois, United States, 60305
United States, Kentucky
Novartis Investigative Site
Florence, Kentucky, United States, 41042
Novartis Investigative Site
Louisville, Kentucky, United States, 40206
United States, Louisiana
Novartis Investigative Site
Opelousas, Louisiana, United States, 70570
United States, Maine
Novartis Investigative Site
Bangor, Maine, United States, 04401
United States, Minnesota
Novartis Investigative Site
Fridley, Minnesota, United States, 55432
United States, Missouri
Novartis Investigative Site
Ozark, Missouri, United States, 65721
Novartis Investigative Site
St. Charles, Missouri, United States, 63301
Novartis Investigative Site
St. Louis, Missouri, United States, 63141
United States, Montana
Novartis Investigative Site
Missoula, Montana, United States, 59804
United States, Nebraska
Novartis Investigative Site
Papillion, Nebraska, United States, 68046
United States, Nevada
Novartis Investigative Site
Henderson, Nevada, United States, 89014
Novartis Investigative Site
Las Vegas, Nevada, United States, 89119
Novartis Investigative Site
Reno, Nevada, United States, 89520
United States, New York
Novartis Investigative Site
Great Neck, New York, United States, 11021
Novartis Investigative Site
Massapequa, New York, United States, 11758
United States, North Carolina
Novartis Investigative Site
Charlotte, North Carolina, United States, 28207
Novartis Investigative Site
Raleigh, North Carolina, United States, 27607
Novartis Investigative Site
Wilmington, North Carolina, United States, 28401
United States, Ohio
Novartis Investigative Site
Columbus, Ohio, United States, 43213
United States, Oregon
Novartis Investigative Site
Medford, Oregon, United States, 97504-8741
Novartis Investigative Site
Portland, Oregon, United States, 97213
United States, Pennsylvania
Novartis Investigative Site
Beaver, Pennsylvania, United States, 15009
Novartis Investigative Site
Erie, Pennsylvania, United States, 16508
Novartis Investigative Site
Pittsburgh, Pennsylvania, United States, 15243
United States, South Carolina
Novartis Investigative Site
Charleston, South Carolina, United States, 29406-7108
Novartis Investigative Site
Spartanburg, South Carolina, United States, 29303
United States, Texas
Novartis Investigative Site
Dallas, Texas, United States, 75216
Novartis Investigative Site
Dallas, Texas, United States, 75246
Novartis Investigative Site
Fort Worth, Texas, United States, 76107
Novartis Investigative Site
Ft. Worth, Texas, United States, 76104
United States, Utah
Novartis Investigative Site
Salt Lake City, Utah, United States, 84107
United States, Virginia
Novartis Investigative Site
Salem, Virginia, United States, 24153
United States, Washington
Novartis Investigative Site
Tacoma, Washington, United States, 98405
United States, Wisconsin
Novartis Investigative Site
Green Bay, Wisconsin, United States, 54311
Argentina
Novartis Investigative Site
Capital Federal, Buenos Aires, Argentina, C1424BSF
Novartis Investigative Site
La Plata, Buenos Aires, Argentina, 1900
Novartis Investigative Site
Mar del Plata, Buenos Aires, Argentina, B7600FZN
Novartis Investigative Site
Mar del Plata, Buenos Aires, Argentina, 7600
Novartis Investigative Site
San Isidro, Buenos Aires, Argentina, B1609EEO
Novartis Investigative Site
Rosario, Santa Fe, Argentina, S2000DBS
Novartis Investigative Site
Rosario, Santa Fe, Argentina, C2000DSR
Novartis Investigative Site
San Miguel de Tucuman, Tucuman, Argentina, T4000DGF
Novartis Investigative Site
San Miguel de Tucuman, Tucuman, Argentina, 4000
Novartis Investigative Site
Buenos Aires, Argentina, C1013AAR
Novartis Investigative Site
Buenos Aires, Argentina, C1186ACB
Novartis Investigative Site
Buenos Aires, Argentina, C1440BRR
Novartis Investigative Site
Buenos Aires, Argentina, C1115AAB
Novartis Investigative Site
Buenos Aires, Argentina, B1842DID
Novartis Investigative Site
Buenos Aires, Argentina, C1125ABE
Novartis Investigative Site
Buenos Aires, Argentina, 1428
Novartis Investigative Site
Buenos aires, Argentina, B1878FNR
Novartis Investigative Site
Buenos aires, Argentina, C1120AAC
Novartis Investigative Site
Buenos Aires, Argentina, B6500EZL
Novartis Investigative Site
Buenos Aires, Argentina, C1425BEA
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Buenos aires, Argentina, B2705XAE
Novartis Investigative Site
Buenos Aires, Argentina, C1405BCH
Novartis Investigative Site
Buenos Aires, Argentina, C1122AAK
Novartis Investigative Site
Buenos Aires, Argentina, C1425AUA
Novartis Investigative Site
Buenos Aires, Argentina, B8000XAV
Novartis Investigative Site
Cordoba, Argentina, X5016KEH
Novartis Investigative Site
Corrientes, Argentina, 3400
Novartis Investigative Site
Mendoza, Argentina, 5500
Novartis Investigative Site
Mendoza, Argentina, M5500CCG
Novartis Investigative Site
Paraná Entre Ríos, Argentina, 3100
Novartis Investigative Site
Santa Fe, Argentina, S3000FIL
Austria
Novartis Investigative Site
Feldbach, Austria, 8330
Novartis Investigative Site
Grieskirchen, Austria, 4710
Novartis Investigative Site
Linz, Austria, 4020
Novartis Investigative Site
Salzburg, Austria, 5020
Novartis Investigative Site
Thalheim bei Wels, Austria, 4600
Canada, Alberta
Novartis Investigative Site
Edmonton, Alberta, Canada, T6G 2B7
Canada, Ontario
Novartis Investigative Site
Mississauga, Ontario, Canada, L5M 2V8
Novartis Investigative Site
Ottawa, Ontario, Canada, K1H 8L6
Canada, Quebec
Novartis Investigative Site
Joliette, Quebec, Canada, J6E 6J2
Novartis Investigative Site
Laval, Quebec, Canada, H7S 2M5
Novartis Investigative Site
Montreal, Quebec, Canada, H2W 1T8
Novartis Investigative Site
Québec, Quebec, Canada, G1G 3Z4
Novartis Investigative Site
St-Romuald, Quebec, Canada, G6W 5M6
Novartis Investigative Site
Trois-Rivières, Quebec, Canada, G8T 7A1
Canada
Novartis Investigative Site
Quebec, Canada, G1P 1J6
Colombia
Novartis Investigative Site
Bogota, Cundinamarca, Colombia
Novartis Investigative Site
Armenia, Colombia
Novartis Investigative Site
Barranquilla, Colombia
Novartis Investigative Site
Bogotá, Colombia
Novartis Investigative Site
Medellin, Colombia
Novartis Investigative Site
Medellín, Colombia
Czech Republic
Novartis Investigative Site
Cesky Krumlov, Czech Republic, 381 01
Novartis Investigative Site
Cvikov, Czech Republic, 471 54
Novartis Investigative Site
Havlickuv Brod, Czech Republic, 580 01
Novartis Investigative Site
Jaromer, Czech Republic, 551 01
Novartis Investigative Site
Karlovy Vary, Czech Republic, 360 66
Novartis Investigative Site
Kromeriz, Czech Republic, 767 55
Novartis Investigative Site
Kutna Hora, Czech Republic, 284 01
Novartis Investigative Site
Kyjov, Czech Republic, 697 01
Novartis Investigative Site
Liberec, Czech Republic, 460 01
Novartis Investigative Site
Pardubice, Czech Republic, 530 09
Novartis Investigative Site
Prague 4, Czech Republic, 142 00
Novartis Investigative Site
Praha 10, Czech Republic, 108 00
Novartis Investigative Site
Praha 9, Czech Republic, 198 00
Novartis Investigative Site
Rokycany, Czech Republic, 337 22
Novartis Investigative Site
Strakonice, Czech Republic, 38601
Novartis Investigative Site
Teplice, Czech Republic, 415 01
Novartis Investigative Site
Zatec, Czech Republic, 438 01
Novartis Investigative Site
Znojmo, Czech Republic, 669 02
Denmark
Novartis Investigative Site
Aalborg, Denmark, DK-9100
Novartis Investigative Site
Copenhagen NV, Denmark, DK-2400
Novartis Investigative Site
Hellerup, Denmark, DK-2900
Novartis Investigative Site
Hvidovre, Denmark, DK-2650
Novartis Investigative Site
Roskilde, Denmark, DK-4000
Novartis Investigative Site
Silkeborg, Denmark, 8600
Novartis Investigative Site
Sønderborg, Denmark, DK-6400
Estonia
Novartis Investigative Site
Tallinn, Estonia, 10138
Novartis Investigative Site
Tallinn, Estonia, 13419
Novartis Investigative Site
Tartu, Estonia, 51014
Finland
Novartis Investigative Site
Helsinki, Finland, 00029
Novartis Investigative Site
Jyvaskyla, Finland, 40100
Novartis Investigative Site
Turku, Finland, FIN-20100
France
Novartis Investigative Site
Bayonne Cedex, France, 64109
Novartis Investigative Site
Beuvry, France, 62660
Novartis Investigative Site
Ferolles-Attily, France, 77150
Novartis Investigative Site
Montpellier, France, 34059
Novartis Investigative Site
Paris, France, 75013
Germany
Novartis Investigative Site
Koblenz, NRW, Germany, 56068
Novartis Investigative Site
Aschaffenburg, Germany, 63739
Novartis Investigative Site
Bamberg, Germany, 96049
Novartis Investigative Site
Berlin, Germany, 13086
Novartis Investigative Site
Berlin, Germany, D-12165
Novartis Investigative Site
Berlin, Germany, 10969
Novartis Investigative Site
Berlin, Germany, 10717
Novartis Investigative Site
Berlin, Germany, 12165
Novartis Investigative Site
Berlin, Germany, 14050
Novartis Investigative Site
Berlin, Germany, 10117
Novartis Investigative Site
Berlin, Germany, 12203
Novartis Investigative Site
Berlin, Germany, 10367
Novartis Investigative Site
Berlin, Germany, 12043
Novartis Investigative Site
Bochum, Germany, 44787
Novartis Investigative Site
Bonn, Germany, 53119
Novartis Investigative Site
Dresden, Germany, 01307
Novartis Investigative Site
Dueren, Germany, 52349
Novartis Investigative Site
Duisburg, Germany, 47057
Novartis Investigative Site
Frankfurt, Germany, 60596
Novartis Investigative Site
Freudenberg, Germany, 57258
Novartis Investigative Site
Fulda, Germany, 36039
Novartis Investigative Site
Gelsenkirchen, Germany, 45879
Novartis Investigative Site
Gummersbach, Germany, 51643
Novartis Investigative Site
Hagen, Germany, 59065
Novartis Investigative Site
Halle, Germany, 06108
Novartis Investigative Site
Hamburg, Germany, 22299
Novartis Investigative Site
Hamburg, Germany, 20354
Novartis Investigative Site
Hannover, Germany, 30167
Novartis Investigative Site
Heidelberg, Germany, 69117
Novartis Investigative Site
Homburg, Germany, 66424
Novartis Investigative Site
Kiel, Germany, 24148
Novartis Investigative Site
Langenfeld, Germany, 40764
Novartis Investigative Site
Leipzig, Germany, 04207
Novartis Investigative Site
Leipzig, Germany, 04357
Novartis Investigative Site
Lübeck, Germany, 23558
Novartis Investigative Site
Marburg, Germany, 35037
Novartis Investigative Site
Muenchen, Germany, 80331
Novartis Investigative Site
Nuernberg, Germany, 90419
Novartis Investigative Site
Oranienburg, Germany, 16515
Novartis Investigative Site
Potsdam, Germany, 14467
Novartis Investigative Site
Radebeul, Germany, 01445
Novartis Investigative Site
Reinfeld, Germany, 23858
Novartis Investigative Site
Saarbruecken, Germany, 66111
Novartis Investigative Site
Schwerte, Germany, 58239
Novartis Investigative Site
Schwetzingen, Germany, 68723
Novartis Investigative Site
Solingen, Germany, 42651
Novartis Investigative Site
Stade, Germany, 21680
Novartis Investigative Site
Teterow, Germany, 17166
Novartis Investigative Site
Wissen, Germany, 57537
Greece
Novartis Investigative Site
Athens, Greece, GR-106 76
Novartis Investigative Site
Athens, Greece, GR 11527
Novartis Investigative Site
Athens, Greece, GR 12461
Novartis Investigative Site
Athens - GR, Greece, 10676
Novartis Investigative Site
Larissa, Greece, 41110
Novartis Investigative Site
Thessaloniki, Greece, GR56403
Novartis Investigative Site
Thessaloniki, Greece, GR 570 10
Hungary
Novartis Investigative Site
Baja, Hungary, 6500
Novartis Investigative Site
Budapest, Hungary, 1125
Novartis Investigative Site
Cegled, Hungary, 2700
Novartis Investigative Site
Debrecen, Hungary, 4032
Novartis Investigative Site
Deszk, Hungary, 6772
Novartis Investigative Site
Eger, Hungary, 3300
Novartis Investigative Site
Makó, Hungary, 6900
Novartis Investigative Site
Mosonmagyarovar, Hungary, 9200
Novartis Investigative Site
Sopron, Hungary, 9400
Novartis Investigative Site
Szarvas, Hungary, 5540
Novartis Investigative Site
Szekszard, Hungary, 7100
India
Novartis Investigative Site
Hyderabad, A.p., India, 500 001
Novartis Investigative Site
Hyderbabd, Andhra Pradesh, India, 500 029
Novartis Investigative Site
New Delhi, Delhi, India, 110029
Novartis Investigative Site
Mysore, Karnataka, India, 570004
Novartis Investigative Site
Nashik, Maharashtra, India, 422005
Novartis Investigative Site
Pune, Maharashtra, India, 411 014
Novartis Investigative Site
Jaipur, Rajasthan, India, 302004
Novartis Investigative Site
Coimbatore, Tamil Nadu, India, 641004
Novartis Investigative Site
Coimbatore, Tamil Nadu, India, 641 002
Novartis Investigative Site
Coimbatore, Tamil Nadu, India, 641014
Novartis Investigative Site
Nagpur - Maharastra, India, 400 012
Novartis Investigative Site
Panjim, India, 403002
Novartis Investigative Site
Secunderabad, India, 500002
Novartis Investigative Site
Trivandrum, India, 695011
Ireland
Novartis Investigative Site
Dublin, Ireland
Novartis Investigative Site
Dublin 15, Ireland
Novartis Investigative Site
Dublin 24, Ireland
Novartis Investigative Site
Dublin 4, Ireland
Novartis Investigative Site
Dublin 9, Ireland
Israel
Novartis Investigative Site
Ashkelon, Israel, 78278
Novartis Investigative Site
Beer-Sheva, Israel, 84101
Novartis Investigative Site
Jerusalem, Israel, 91120
Novartis Investigative Site
Jerusalem, Israel, 91031
Novartis Investigative Site
Kfar-Sava, Israel, 44281
Novartis Investigative Site
Petach Tikva, Israel, 49100
Novartis Investigative Site
Ramat Gan, Israel, 52621
Novartis Investigative Site
Rehovot, Israel, 76100
Novartis Investigative Site
Tel-Aviv, Israel, 64239
Italy
Novartis Investigative Site
Osimo, AN, Italy, 60027
Novartis Investigative Site
Catania, CT, Italy, 95125
Novartis Investigative Site
Foggia, FG, Italy, 71100
Novartis Investigative Site
Firenze, FI, Italy, 50134
Novartis Investigative Site
Arenzano, GE, Italy, 16011
Novartis Investigative Site
Milano, MI, Italy, 20121
Novartis Investigative Site
Abano Terme, PD, Italy, 35031
Novartis Investigative Site
Perugia, PG, Italy, 06129
Novartis Investigative Site
Pisa, PI, Italy, 56124
Novartis Investigative Site
Pavia, PV, Italy, 27100
Novartis Investigative Site
Roma, RM, Italy, 00128
Novartis Investigative Site
Riccione, RN, Italy, 47838
Novartis Investigative Site
Siena, SI, Italy, 53100
Novartis Investigative Site
Pietra Ligure, SV, Italy, 17027
Novartis Investigative Site
Montecchio Maggiore, VI, Italy, 36075
Novartis Investigative Site
Pisa, Italy, 56124
Mexico
Novartis Investigative Site
Mexico, Distrito Federal, Mexico, 14050
Novartis Investigative Site
Mexico, Distrito Federal, Mexico, 06726
Novartis Investigative Site
Guadalajara, Jalisco, Mexico, 44670
Novartis Investigative Site
Zapopan, Jalisco, Mexico, 45200
Novartis Investigative Site
Monterrey, Nuevo León, Mexico, 64450
Novartis Investigative Site
San Luis Potosí, Mexico, 78218
Netherlands
Novartis Investigative Site
Almelo, Netherlands, 7609 PP
Novartis Investigative Site
Breda, Netherlands, 4819 EV
Novartis Investigative Site
Dordrecht, Netherlands, 3318AT
Novartis Investigative Site
Drachten, Netherlands, 9200 DA
Novartis Investigative Site
Enschede, Netherlands, 7513 ER
Novartis Investigative Site
Harderwijk, Netherlands, 3840 AC
Novartis Investigative Site
Helmond, Netherlands, 5707 HA
Novartis Investigative Site
Hoofddorp, Netherlands, 2134 TM
Novartis Investigative Site
Hoorn, Netherlands, 1624 NP
Novartis Investigative Site
Leeuwarden, Netherlands, 8934 AD
Novartis Investigative Site
Roermond, Netherlands, 6043 CV
Novartis Investigative Site
Veldhoven, Netherlands, 5504 DB
Novartis Investigative Site
Voorburg, Netherlands, 2275 CX
Peru
Novartis Investigative Site
Cercado de Lima, Lima, Peru, 01
Novartis Investigative Site
San Borja, Lima, Peru, 41
Novartis Investigative Site
San Isidro, Lima, Peru, 27
Novartis Investigative Site
San Martin de Porres, Lima, Peru, 31
Novartis Investigative Site
San Miguel, Lima, Peru, 32
Novartis Investigative Site
Santiago de Surco, Lima, Peru, 33
Philippines
Novartis Investigative Site
Quezon City, Metro Manila, Philippines, 1109
Novartis Investigative Site
Bulacan, Philippines, 3020
Novartis Investigative Site
Las Pinas, Philippines, 1740
Novartis Investigative Site
Manila, Philippines
Novartis Investigative Site
Quezon City, Philippines, 1100
Poland
Novartis Investigative Site
Bialystok, Poland, 15-010
Novartis Investigative Site
Katowice, Poland, 40-752
Novartis Investigative Site
Krakow, Poland, 31-159
Novartis Investigative Site
Krakow, Poland, 30-067
Novartis Investigative Site
Lublin, Poland, 20-637
Novartis Investigative Site
Mrozy, Poland, 05-320
Novartis Investigative Site
Warszawa, Poland, 01-456
Puerto Rico
Novartis Investigative Site
Humacao, Puerto Rico, 00791
Russian Federation
Novartis Investigative Site
Kazan, Tatarstan Republic, Russian Federation, 420015
Novartis Investigative Site
Barnaul, Russian Federation, 656045
Novartis Investigative Site
Chelyabinsk, Russian Federation, 454021
Novartis Investigative Site
Ekaterinburg, Russian Federation, 620109
Novartis Investigative Site
Moscow, Russian Federation, 127018
Novartis Investigative Site
Moscow, Russian Federation, 105229
Novartis Investigative Site
Rostov-on-Don, Russian Federation, 344090
Novartis Investigative Site
Ryazan, Russian Federation, 390026
Novartis Investigative Site
S.-Petersburg, Russian Federation, 196247
Novartis Investigative Site
Samara, Russian Federation, 443079
Novartis Investigative Site
Sankt-Peterburg, Russian Federation, 197022
Novartis Investigative Site
St-Petersburg, Russian Federation, 193312
Novartis Investigative Site
St. Petersburg, Russian Federation, 191015
Novartis Investigative Site
St. Petersburg, Russian Federation, 198013
Novartis Investigative Site
St. Petersburg, Russian Federation, 194354
Novartis Investigative Site
St.Petersburg, Russian Federation, 198044
Novartis Investigative Site
Yaroslavl, Russian Federation, 150010
Slovakia
Novartis Investigative Site
Banska Bystrica, Slovak Republic, Slovakia, 975 17
Novartis Investigative Site
Bojnice, Slovak Republic, Slovakia, 972 01
Novartis Investigative Site
Humenne, Slovak Republic, Slovakia, 066 01
Novartis Investigative Site
Partizanske, Slovak Republic, Slovakia, 958 01
Novartis Investigative Site
Kosice, Slovakia, 040 01
Novartis Investigative Site
Kralovsky Chlmec, Slovakia, 077 01
Novartis Investigative Site
Martin, Slovakia, 03601
Novartis Investigative Site
Presov, Slovakia, 080 01
Novartis Investigative Site
Trnava, Slovakia, 917 75
South Africa
Novartis Investigative Site
Durban, South Africa, 4001
Novartis Investigative Site
Newtown, Johannesburg, South Africa, 2193
Novartis Investigative Site
Pretoria, South Africa
Novartis Investigative Site
Pretoria, South Africa, 0184
Novartis Investigative Site
Pretoria, South Africa, 0181
Spain
Novartis Investigative Site
Malaga, Andalucia, Spain, 29010
Novartis Investigative Site
L'Hospitalet de Llobregat, Cataluña, Spain, 08907
Novartis Investigative Site
Valencia, Comunidad Valenciana, Spain
Novartis Investigative Site
La Coruna, Galicia, Spain, 15006
Novartis Investigative Site
Alicante, Spain, 03114
United Kingdom
Novartis Investigative Site
Stockton, Cleveland, United Kingdom, TS19 8PE
Novartis Investigative Site
Sneinton, Nottingham, United Kingdom, NG3 7DQ
Novartis Investigative Site
Taunton, Somerset, United Kingdom, TA1 3JL
Novartis Investigative Site
Chertsey, Surrey, United Kingdom, KT16 0PZ
Novartis Investigative Site
Blackpool, United Kingdom, FY3 8NR
Novartis Investigative Site
Bradford, United Kingdom, BD9 6RJ
Novartis Investigative Site
Bristol, United Kingdom, BS10 5NB
Novartis Investigative Site
Coventry, United Kingdom, CV6 4DD
Novartis Investigative Site
Gillingham, United Kingdom, ME7 5NY
Novartis Investigative Site
Glasgow, United Kingdom, G21 3UW
Novartis Investigative Site
Hereford, United Kingdom, HR1 2ER
Novartis Investigative Site
Huntingdon, United Kingdom, PE29 6NT
Novartis Investigative Site
London, United Kingdom, NW3 2PR
Novartis Investigative Site
Manchester, United Kingdom, M23 9QZ
Novartis Investigative Site
Merseyside, United Kingdom, CH49 5PE
Novartis Investigative Site
Portsmouth, United Kingdom, PO6 3AD
Novartis Investigative Site
Telford, United Kingdom, TF1 6TF
Novartis Investigative Site
Wolverhampton, United Kingdom, WV10 0QP
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

No publications provided by Novartis

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT01120691     History of Changes
Other Study ID Numbers: CQVA149A2304, 2009-013256-69
Study First Received: May 5, 2010
Results First Received: July 9, 2013
Last Updated: October 29, 2013
Health Authority: United States: Food and Drug Administration
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Australia: Department of Health and Ageing Therapeutic Goods Administration
Belgium: Federal Agency for Medicinal Products and Health Products
Brazil: National Health Surveillance Agency
Canada: Health Canada
Chile: Comisión Nacional de Investigación Científica y Tecnológica
Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos
Czech Republic: State Institute for Drug Control
Denmark: Danish Medicines Agency
Estonia: The State Agency of Medicine
Finland: Finnish Medicines Agency
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Greece: National Organization of Medicines
Guatemala: Ministry of Public Health and Social Assistance
Hungary: National Institute of Pharmacy
India: Drugs Controller General of India
Ireland: Irish Medicines Board
Israel: Ministry of Health
Italy: The Italian Medicines Agency
Korea: Food and Drug Administration
Malaysia: Ministry of Health
Mexico: Ministry of Health
Netherlands: Medicines Evaluation Board (MEB)
New Zealand: Food Safety Authority
Norway: Norwegian Medicines Agency
Peru: Ministry of Health
Philippines: Bureau of Food and Drugs
Poland: Ministry of Health
Romania: National Medicines Agency
Russia: Ministry of Health of the Russian Federation
Singapore: Health Sciences Authority
South Africa: Department of Health
Spain: Spanish Agency of Medicines
Thailand: Food and Drug Administration
Turkey: Ministry of Health
Ukraine: Ministry of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Novartis:
QVA149
NVA237
COPD
exacerbation
combination bronchodilator

Additional relevant MeSH terms:
Lung Diseases
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Respiratory Tract Diseases
Albuterol
Tiotropium
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Parasympatholytics
Cholinergic Antagonists
Cholinergic Agents

ClinicalTrials.gov processed this record on August 21, 2014